MEDCu Technologies

Company Overview

Snapshot

Founded in September 2016 by Danny Lustiger and Gadi Borkow, MEDCu Technologies operates with 11–50 employees. The company is in the Pre-Funding stage and has developed an innovative copper-based antimicrobial wound dressing. In November 2018, the company received 510(k) FDA Premarket Notification for its Medcu Antibacterial Wound Dressings With Copper-oxide.

Business overview

MEDCu Technologies is a biotech company specializing in the development of cost-effective antimicrobial wound dressings. Its core product, the MedCu Wound Dressing, incorporates copper microparticles within an absorbent internal layer and nonwoven external layers. This design provides a barrier against bacterial contamination while supporting the healing process. The company's products are designed for acute, diabetic, and chronic wounds, leveraging over 15 years of research in copper particle utilization, protected by more than 30 patents worldwide. MEDCu Technologies operates within the Health Tech & Life Sciences sector, specifically targeting the medical technologies, biotechnology, and dermatology markets.

Strategic signal

In October 2021, MEDCu Technologies' innovative copper dressing was highlighted for its effectiveness in treating diabetic wounds. This signals the company's potential to address significant unmet medical needs in chronic wound care, validating its copper-based technology and positioning it as a key player in advanced wound management solutions.

Company Intelligence Q&A

What is MEDCu Technologies' primary product?

MEDCu Technologies' primary product is the MedCu Wound Dressing, a copper-based antimicrobial wound dressing designed to prevent bacterial contamination and support healing for acute, diabetic, and chronic wounds.

When was MEDCu Technologies founded and by whom?

MEDCu Technologies was founded in September 2016 by Danny Lustiger and Gadi Borkow.

Has MEDCu Technologies received any regulatory clearances for its products?

In November 2018, MEDCu Technologies received 510(k) FDA Premarket Notification K180643 for its Medcu Antibacterial Wound Dressings With Copper-oxide.

What is the strategic importance of copper in MEDCu Technologies' products?

MEDCu Technologies utilizes copper microparticles in its wound dressings to provide an antimicrobial barrier against bacterial contamination, a technology developed through over 15 years of research and protected by more than 30 patents globally.

What market need does MEDCu Technologies address?

MEDCu Technologies addresses the need for effective and cost-efficient solutions for managing acute, diabetic, and chronic wounds, leveraging its patented copper-based technology to improve healing outcomes.